Global BV News: Spotlight on pharma firms in KPMG’s 4Q20 valuation brief

BVWireIssue #219-2
December 9, 2020

global business valuation
business valuation profession, cost of capital, international business valuation, coronavirus, COVID-19

COVID-19 continues to dominate a lot of the discussion in KPMG’s Quarterly Brief—International Valuation Newsletter for the fourth quarter of 2020. There’s a discussion of the challenges of valuation in the pharmaceutical and biotechnology sector that points out that many analysts are using probability-weighted cash flow methods and risk-adjusted net present value to deal with these challenges. There is also an update on recent capital market data, including major stock market performances, valuation multiples, current risk-free rates for major currencies, and country risk premiums. The full issue is available if you click here.
Please let us know if you have any comments about this article or enhancements you would like to see.